David A. Moore
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Primary care and community-based screening for Chagas disease in London, United Kingdom, August 2023 to January 2025.
Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Published: February 13, 2026
Disseminated Tuberculosis Driving Secondary Haemophagocytic Lymphohistiocytosis Following Adalimumab and Treatment for Latent Tuberculosis.
Journal: British journal of hospital medicine (London, England : 2005)
Published: March 26, 2025
Deep cell phenotyping and spatial analysis of multiplexed imaging with TRACERx-PHLEX.
Journal: Nature communications
Published: October 11, 2023
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Journal: The Lancet. Respiratory medicine
Published: September 01, 2023
Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.
Journal: The Journal of pathology
Published: June 15, 2023
Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
Journal: The Journal of pathology
Published: April 21, 2023
Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy.
Journal: Cancers
Published: July 15, 2022
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Journal: Cancer cell
Published: March 17, 2021
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
Journal: Scientific reports
Published: September 21, 2020
Host transcriptional response to TB preventive therapy differentiates two sub-groups of IGRA-positive individuals.
Journal: Tuberculosis (Edinburgh, Scotland)
Published: August 02, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Journal: The Journal of pathology
Published: February 06, 2020
Last Updated: 09/26/2026